ARTICLE
18 February 2013

Generic Damages In Life Sciences Patent Litigation: Strategic Considerations (Video Content)

GW
Gowling WLG

Contributor

Gowling WLG is an international law firm built on the belief that the best way to serve clients is to be in tune with their world, aligned with their opportunity and ambitious for their success. Our 1,400+ legal professionals and support teams apply in-depth sector expertise to understand and support our clients’ businesses.
A discussion on the strategic considerations relating to generic damages in life sciences patent litigation.
Canada Food, Drugs, Healthcare, Life Sciences
Gowling WLG are most popular:
  • within Compliance and Tax topic(s)
  • with Senior Company Executives, HR and Finance and Tax Executives
  • in Canada
  • with readers working within the Healthcare industries

In this presentation,  Christopher Van Barr and Kiernan Murphy discuss strategic considerations relating to generic damages in life sciences patent litigation. 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More